Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 16/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19047572 | 0.85 | HDAC4 (0.72) | HDAC4HDAC6HDAC1 | |
| SCHEMBL4411696 | 0.81 | S1PR1 (0.52) | HDAC4HDAC6CA12CA1CA2 | |
| SCHEMBL4227737 | 0.79 | NR1H4 (0.56) | HDAC4HDAC6HDAC1 | |
| SCHEMBL7019255 | 0.78 | NR1H4 (0.54) | HDAC4HDAC6HDAC1 | |
| SCHEMBL17377373 | 0.77 | NOTUM (0.53) | HDAC4HDAC6 | |
| SCHEMBL4414333 | 0.76 | CA2 (0.50) | HDAC4HDAC6CA12CA1CA2 | |
| SCHEMBL5569323 | 0.76 | DPP4 (0.53) | HDAC4HDAC6CA12CA1CA2 | |
| SCHEMBL11166733 | 0.76 | MAPT (0.57) | HDAC4HDAC6HDAC1 | |
| SCHEMBL3634573 | 0.75 | NR1H4 (0.57) | HDAC4 | |
| SCHEMBL11760941 | 0.74 | FLT3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| CN-1905868-A | DPP-IV inhibitors | GRAFFINITY PHARMACEUTICALS AG (CH) | 2007-01-31 | — | — | CN | disclosed |
| EP-1613304-A1 | DPP-IV INHIBITORS | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | HDAC4 384/4885HDAC6 1507/4885HDAC1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.